sales@angenesci.com
Login | Register
logo
Structures Search
Home Other Building Blocks Monomethyl auristatin e

Monomethyl auristatin e

CAS No.:
474645-27-7
Catalog Number:
AG00359V
Molecular Formula:
C39H67N5O7
Molecular Weight:
717.9786
Pack Size
Purity
Availability
Location
Price(USD)
Quantity
  
5mg
95%
In Stock USA
United States
$123
- +
10mg
95%
In Stock USA
United States
$221
- +
25mg
95%
In Stock USA
United States
$366
- +
100mg
95%
In Stock USA
United States
$1061
- +
Product Description
Catalog Number:
AG00359V
Chemical Name:
Monomethyl auristatin e
CAS Number:
474645-27-7
Molecular Formula:
C39H67N5O7
Molecular Weight:
717.9786
MDL Number:
MFCD22124498
IUPAC Name:
(2S)-N-[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]-3-methyl-2-(methylamino)butanamide
InChI:
InChI=1S/C39H67N5O7/c1-13-25(6)34(43(10)39(49)33(24(4)5)42-38(48)32(40-9)23(2)3)30(50-11)22-31(45)44-21-17-20-29(44)36(51-12)26(7)37(47)41-27(8)35(46)28-18-15-14-16-19-28/h14-16,18-19,23-27,29-30,32-36,40,46H,13,17,20-22H2,1-12H3,(H,41,47)(H,42,48)/t25-,26+,27+,29-,30+,32-,33-,34-,35+,36+/m0/s1
InChI Key:
DASWEROEPLKSEI-UIJRFTGLSA-N
SMILES:
CN[C@H](C(=O)NC(=O)[C@@H](N(C([C@@H](CC(=O)N1CCC[C@H]1C([C@H](C(=O)N[C@@H]([C@H](c1ccccc1)O)C)C)OC)OC)[C@H](CC)C)C)C(C)C)C(C)C
UNII:
V7I58RC5EJ
Properties
Complexity:
1100  
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
1  
Defined Atom Stereocenter Count:
10  
Defined Bond Stereocenter Count:
0
Exact Mass:
717.504g/mol
Formal Charge:
0
Heavy Atom Count:
51  
Hydrogen Bond Acceptor Count:
8  
Hydrogen Bond Donor Count:
4  
Isotope Atom Count:
0
Molecular Weight:
717.993g/mol
Monoisotopic Mass:
717.504g/mol
Rotatable Bond Count:
20  
Topological Polar Surface Area:
150A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
XLogP3:
4.1  
Literature
Title Journal
Native intact mass determination of antibodies conjugated with monomethyl Auristatin E and F at interchain cysteine residues. Analytical chemistry 20120320
Targeting cell surface alpha(v)beta(3) integrin increases therapeutic efficacies of a legumain protease-activated auristatin prodrug. Molecular pharmaceutics 20120101
Brentuximab vedotin and crizotinib in anaplastic large-cell lymphoma. Cancer journal (Sudbury, Mass.) 20120101
Glembatumumab vedotin, a conjugate of an anti-glycoprotein non-metastatic melanoma protein B mAb and monomethyl auristatin E for the treatment of melanoma and breast cancer. Current opinion in molecular therapeutics 20100401
EphA2 immunoconjugate as molecularly targeted chemotherapy for ovarian carcinoma. Journal of the National Cancer Institute 20090902
Potent antitumor activity of the anti-CD19 auristatin antibody drug conjugate hBU12-vcMMAE against rituximab-sensitive and -resistant lymphomas. Blood 20090430
Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nature biotechnology 20080801
Combination of the anti-CD30-auristatin-E antibody-drug conjugate (SGN-35) with chemotherapy improves antitumour activity in Hodgkin lymphoma. British journal of haematology 20080701
Engineered antibody-drug conjugates with defined sites and stoichiometries of drug attachment. Protein engineering, design & selection : PEDS 20060701
Potent cytotoxicity of an auristatin-containing antibody-drug conjugate targeting melanoma cells expressing melanotransferrin/p97. Molecular cancer therapeutics 20060601
Lymphocyte activation antigen CD70 expressed by renal cell carcinoma is a potential therapeutic target for anti-CD70 antibody-drug conjugates. Cancer research 20060215
Evaluation of RGD-targeted albumin carriers for specific delivery of auristatin E to tumor blood vessels. Bioconjugate chemistry 20060101
Efficient elimination of B-lineage lymphomas by anti-CD20-auristatin conjugates. Clinical cancer research : an official journal of the American Association for Cancer Research 20041201
Properties